Second edition

x.qxd 3/10/08 10:01 AM Page 711
post-anoxic encephalopathy 169,
171, 462
post-concussion syndrome 458
progressive supranuclear palsy 168,
353
sarcoidosis 172, 555
spinocerebellar ataxia 363
stroke 163, 164, 166–7, 281
subdural hematoma (traumatic)
455
syphilis 166, 509
systemic lupus erythematosus 166,
168, 172, 549, 550
Whipple’s disease 169, 172
lacunar see lacunar dementia
multi-infarct see multi-infarct dementia
myoclonus with 75, 76, 163, 164, 169
parkinsonism with 89, 163, 164, 167–8
treatment 173, 434
pharmacological see drug therapy
vascular, definition 433
dementia pugilistica 168, 170, 456–7
demyelinization
central pontine myelinolysis 479, 480
Marchiafava–Bignami disease 695
radiation encephalopathy 458, 459
vitamin B12 deficiency 466, 467
denial, emotionally-motivated,
anosognosia for vs 61
dentatorubropallidoluysian atrophy
360–1
clinical features 360
dementia 169, 170
psychosis 241
differential diagnosis 361
spinocerebellar ataxia 364
depersonalization 132–3
observing for 8–9
in simple partial seizures 251
depression (depressed mood) 208–14,
624–9
clinical features 208–9, 624–6
agitation 209, 225, 625
apathy 214
delusions and hallucinations in 144,
625–6, 689
depersonalization 133
Schneiderian first rank symptoms
147–8
sleep disturbances 208–9, 586, 625
in dementia 173, 209
Alzheimer’s disease 212, 336
dementia in 165
differential diagnosis 213, 627
akinesia 91, 213
Alzheimer’s disease 339
amnesia 187
anxiety 227
apathy 214–15
attention-deficit/hyperactivity
disorder 419
Briquet’s syndrome 300
flattened affect 139
hypochondriasis 301
insomnia (primary) 586
mutism 119
psychosis 243
schizophrenia 612
etiology 209–13, 538, 626–7
adrenocortical insufficiency 537
bipolar disorder 620, 623
brain tumors 213, 597
concussion 457, 458
Cushing’s syndrome 212, 534, 536
dementia see subheading above
diffuse Lewy body disease 212, 351,
352
Down’s syndrome 213, 407
hyperthyroidism 211, 538
hypothyroidism 212, 539, 539
Kleine–Levin syndrome 580–1
multiple sclerosis 212–13, 545, 548
Parkinson’s disease 212, 345, 350
post-psychotic depression 614
post-partum depression see postpartum
period
schizoaffective disorder 211, 615
simple partial seizures 252
sleep apnea 211, 578
stroke 212, 281–2
systemic lupus erythematosus 213,
549, 550
traumatic brain injury 292
major see depressive disorder, major
observing for 6
recurrence with nicotine abstinence
675
resistant 628
treatment 213–14, 225, 281–2, 292,
350, 627–9, 689
in bipolar disorder 623
tremor and 73, 74
depressive disorder, major 624–9
clinical features 624–6
course 208
differential diagnosis 627
generalized anxiety disorder 642
post-partum 630
post-traumatic stress disorder 641
schizoaffective disorder 615
schizophrenia 611, 612
etiology 636–7
recurrence with nicotine abstinence
675
treatment 627–9
deprivation, severe, vs developmental
dysphasia 421
desipramine, Tourette’s syndrome 371
desmopressin, nocturnal enuresis 575
detoxification, rapid/ultra-rapid, opioid
673
developmental and/or congenital disorders
and factors 403–32
amusia 137
Index 711
dysgraphia 51, 422
dysphasia see dysphasia
seizures 261, 266–7
stuttering 119–20, 120, 423–4
see also childhood onset and specific
disorders
dexamethasone, brain tumors 600
dexamethasone suppression test 535
dextroamphetamine 656
diagnostic assessment 3–42
dialysis dementia 169, 171, 222, 476–7
dialysis dysequilibrium syndrome 477
dietary deficiency
folate 468
niacin 469
thiamine 470
diffuse axonal injury see axonal injury
diffuse Lewy body disease see Lewy body
disease
diffusion-weighted MRI 18
disconnection syndrome, apraxia as part of
56
disinhibition in frontal lobe syndrome
244, 245
disorganized schizophrenia 608–9
disorientation 9
delusional (�reduplicative paramnesia)
135–6
of place see topographical disorientation
disseminated intravascular coagulation vs
thrombotic thrombocytopenic
purpura 446
dissociative amnesia 186
distractibility 216
disulfiram
alcoholism 667
dementia associated with 171
divalproex see valproic acid and sodium
valproate
domoic acid intoxication 263
donepezil, Alzheimer’s disease 339
dopa (L-dopa) see levodopa
dopamine blockers-induced conditions
neuroleptic malignant syndrome 684
tardive dyskinesia 686
dopaminergic drugs (incl. dopamine
agonists)
adverse effects 349–50
psychosis 240
therapeutic use
neuroleptic malignant syndrome
684–5
Parkinson’s disease 348–9, 349
restless legs syndrome 582
double orientation (�reduplicative
paramnesia) 135–6
Down’s syndrome (trisomy 21) 188, 407,
407–8
clinical features 407
dementia 171, 407
depression 213, 407
seizures 266, 407